StaveMD review

The injection prices and current refund policy are more specific than a starting-price headline. Compare four-week billing with calendar-month competitors, give advance notice to stop renewal and confirm the terms attached to your order.

StaveMD is a telehealth technology platform. Its terms identify OpenLoop Healthcare Partners, PC and affiliated professional corporations as clinical providers. The linked OpenLoop consent says the treating professional entity is identified at the visit; it does not assign every listed OpenLoop affiliate to a StaveMD patient. StaveMD does not itself practice medicine or dispense medication.

Programs are intended for adults aged 18 or older. StaveMD advertises service in all 50 states and Washington, DC, subject to treatment and provider availability. A licensed clinician reviews the intake and decides whether to prescribe; completing an eligibility check does not guarantee treatment.

Public terms list Red Rock, Health Warehouse, Precision Medicine and Triad Rx as possible pharmacies, without assigning one to a particular prescription. The selected pharmacy, medication supply, lab requirements and any lab charges need confirmation. The plan includes shipping, but the public pages do not establish a fixed clinical-review or pharmacy-processing time. StaveMD is self-pay and advertises HSA/FSA eligibility, subject to the account’s rules.

For new patients, compounded semaglutide injection is $149 charged at checkout for the first four weeks, then $279 every four weeks on the monthly plan. Tirzepatide injection is $349 every four weeks. Provider review, prescription and shipping are included; StaveMD states there is no separate membership fee or dose-increase surcharge. Four-week billing is not calendar-month billing.

The home page also advertises an oral tablet at $169 initially, then $279 every four weeks, but does not identify the molecule or formulation. This is not an established oral semaglutide or tirzepatide offer. Longer plans are described as prepaid without automatic renewal; the public monthly headlines do not establish their selected full charge. The refund policy’s $597 allocation example is not proof of an available treatment SKU.

Cancel monthly renewal through the portal or by emailing support at least 48 hours before the next bill. The policy says a later request stops any refill not yet committed to fulfillment; medication already ordered is not automatically refundable solely because you cancel. Provider-declined initial orders receive the whole payment back.

For new GLP-1 orders placed on or after October 27, 2026, the first-month commitment allows one refund request within 30 days of first delivery, without a weight-loss target or explanation. It refunds the actual discounted first-four-week payment and associated tax, with no deduction for included review or shipping. The request also cancels future refills. A twelve-week supply is billed once without renewal; its first-month allocation is one third, and unsent shipments are separately refunded at their allocated discounted price. StaveMD states acknowledgment within two business days, a decision within five and approved refunds within ten, plus bank processing. Older order dates have separate policies; the earlier broad weight-loss guarantee does not describe new orders.

The injection pages identify compounded semaglutide and tirzepatide. StaveMD distinguishes these finished products from Ozempic/Wegovy and Mounjaro/Zepbound; compounded medicines are not FDA-approved or generic equivalents of those brands. The oral tablet’s molecule and formulation remain unclear. Clinical-trial results shown on the site are for branded medicines, not demonstrated outcomes for StaveMD’s compounded prescriptions.